The best defensive stocks to balance risk and return combine durable cash flows, essential services, and key growth metrics.

The leading approach to the simplex method, a widely used technique for balancing complex logistical constraints, can’t get ...

Overview: Alphabet’s AI strategy is already driving real revenue growth, led by strong performance in Google Cloud.A $155 billion cloud backlog provides clear v ...

WorkBeaver presently functions by using a menu-driven interface that asks users for prompt-based descriptions of tasks. The ...

Gemini's mini app builder uses Opal tech to deliver a new kind of Gem, and it's a game-changer for quick and simple web ...

Background Fermented foods are a promising yet underexplored intervention for influencing brain function and mental health through the gut–brain axis. Objective The objective of this study was to ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal-Weight" and ...

Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion.

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...